Cargando…

Low calcium dialysate combined with CaCO(3) in hyperphosphatemia in hemodialysis patients

This aim of this study was to observe the effects of the application of low calcium dialysate (LCD) combined with oral administration of CaCO(3) in the treatment of hyperphosphatemia, as well as blood Ca(2+), calcium-phosphate product (CPP), parathyroid hormone (PTH) and blood pressure in patients u...

Descripción completa

Detalles Bibliográficos
Autores principales: GAO, ZHUO, LUN, LI-DE, LI, XIN-LUN
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3702715/
https://www.ncbi.nlm.nih.gov/pubmed/23837063
http://dx.doi.org/10.3892/etm.2013.1067
_version_ 1782275855995633664
author GAO, ZHUO
LUN, LI-DE
LI, XIN-LUN
author_facet GAO, ZHUO
LUN, LI-DE
LI, XIN-LUN
author_sort GAO, ZHUO
collection PubMed
description This aim of this study was to observe the effects of the application of low calcium dialysate (LCD) combined with oral administration of CaCO(3) in the treatment of hyperphosphatemia, as well as blood Ca(2+), calcium-phosphate product (CPP), parathyroid hormone (PTH) and blood pressure in patients undergoing hemodialysis. Thirty-one maintenance hemodialysis (MHD) patients with hyperphosphatemia, but normal blood Ca(2+), underwent dialysis with an initial dialy-sate Ca(2+) concentration (DCa) of 1.50 mmol/l for six months and then with 1.25 mmol/l for six months. The patients who underwent dialysis with a DCa of 1.25 mmol/l were treated orally with 0.3 g CaCO(3) tablets three times a day. In the third and sixth months [observation end point (OEP)] of the dialysis, the concentrations of Ca(2+), phosphorus and intact PTH (iPTH) were measured; blood pressure and side-effects prior to and following dialysis were also observed. The Ca(2+), CPP and iPTH levels increased (P<0.05) in the sixth month of treatment with a DCa of 1.50 mmol/l. However, the Ca(2+) concentration declined to a certain degree, CPPs decreased significantly (P<0.05) and the iPTH concentration increased following treatment with a DCa of 1.25 mmol/l for six months. The incidence rate of adverse effects of LCD was 12.9% (4/31); the effects were mainly muscle spasms, hypotension and elevated PTH. The periodic application of LCD combined with the oral administration of CaCO(3) effectively reduced serum phosphorus and CPPs among MHD patients with hyperphosphatemia, indicating that the treatment may be used clinically.
format Online
Article
Text
id pubmed-3702715
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-37027152013-07-08 Low calcium dialysate combined with CaCO(3) in hyperphosphatemia in hemodialysis patients GAO, ZHUO LUN, LI-DE LI, XIN-LUN Exp Ther Med Articles This aim of this study was to observe the effects of the application of low calcium dialysate (LCD) combined with oral administration of CaCO(3) in the treatment of hyperphosphatemia, as well as blood Ca(2+), calcium-phosphate product (CPP), parathyroid hormone (PTH) and blood pressure in patients undergoing hemodialysis. Thirty-one maintenance hemodialysis (MHD) patients with hyperphosphatemia, but normal blood Ca(2+), underwent dialysis with an initial dialy-sate Ca(2+) concentration (DCa) of 1.50 mmol/l for six months and then with 1.25 mmol/l for six months. The patients who underwent dialysis with a DCa of 1.25 mmol/l were treated orally with 0.3 g CaCO(3) tablets three times a day. In the third and sixth months [observation end point (OEP)] of the dialysis, the concentrations of Ca(2+), phosphorus and intact PTH (iPTH) were measured; blood pressure and side-effects prior to and following dialysis were also observed. The Ca(2+), CPP and iPTH levels increased (P<0.05) in the sixth month of treatment with a DCa of 1.50 mmol/l. However, the Ca(2+) concentration declined to a certain degree, CPPs decreased significantly (P<0.05) and the iPTH concentration increased following treatment with a DCa of 1.25 mmol/l for six months. The incidence rate of adverse effects of LCD was 12.9% (4/31); the effects were mainly muscle spasms, hypotension and elevated PTH. The periodic application of LCD combined with the oral administration of CaCO(3) effectively reduced serum phosphorus and CPPs among MHD patients with hyperphosphatemia, indicating that the treatment may be used clinically. D.A. Spandidos 2013-06 2013-04-17 /pmc/articles/PMC3702715/ /pubmed/23837063 http://dx.doi.org/10.3892/etm.2013.1067 Text en Copyright © 2013, Spandidos Publications http://creativecommons.org/licenses/by/3.0 This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Articles
GAO, ZHUO
LUN, LI-DE
LI, XIN-LUN
Low calcium dialysate combined with CaCO(3) in hyperphosphatemia in hemodialysis patients
title Low calcium dialysate combined with CaCO(3) in hyperphosphatemia in hemodialysis patients
title_full Low calcium dialysate combined with CaCO(3) in hyperphosphatemia in hemodialysis patients
title_fullStr Low calcium dialysate combined with CaCO(3) in hyperphosphatemia in hemodialysis patients
title_full_unstemmed Low calcium dialysate combined with CaCO(3) in hyperphosphatemia in hemodialysis patients
title_short Low calcium dialysate combined with CaCO(3) in hyperphosphatemia in hemodialysis patients
title_sort low calcium dialysate combined with caco(3) in hyperphosphatemia in hemodialysis patients
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3702715/
https://www.ncbi.nlm.nih.gov/pubmed/23837063
http://dx.doi.org/10.3892/etm.2013.1067
work_keys_str_mv AT gaozhuo lowcalciumdialysatecombinedwithcaco3inhyperphosphatemiainhemodialysispatients
AT lunlide lowcalciumdialysatecombinedwithcaco3inhyperphosphatemiainhemodialysispatients
AT lixinlun lowcalciumdialysatecombinedwithcaco3inhyperphosphatemiainhemodialysispatients